Blood test could guide use of anti-inflammatory drug celecoxib to reduce risk of colon cancer recurrence
A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham ...
EurekAlert!6d
Blood test from Alliance trial guides use of anti-inflammatory drug to lower colon cancer recurrence risk
The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that ...
EurekAlert!6d
Blood test could guide use of anti-inflammatory drug celecoxib to reduce risk of colon cancer recurrence
The analysis showed that patients with positive blood tests for circulating tumor DNA (ctDNA) had worse outcomes in general, but those who were treated with celecoxib, a non-steroidal anti ...